Silverarc Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Silverarc Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-23,054	Closed	-$2.62M	–	112
2022 Q4	$2.62M	Buy	23,054 +12,923	+128%	+$1.07M	0.9%	47
2022 Q3	$627K	Sell	10,131 -62,056	-86%	-$4.34M	0.27%	65
2022 Q2	$5.76M	Buy	72,187 +4,745	+7%	+$449K	2.7%	21
2022 Q1	$7.1K	Buy	67,442 +5,742	+9%	+$560K	3.36%	9
2021 Q4	$6.65M	Buy	61,700 +9,231	+18%	+$1.01M	2.98%	12
2021 Q3	$5.75M	Buy	52,469 +2,434	+5%	+$253K	3.33%	6
2021 Q2	$4.68K	Buy	50,035 +1,559	+3%	+$143K	2.29%	14
2021 Q1	$4.46M	Buy	48,476 +18,476	+62%	+$1.56M	2.5%	10
2020 Q4	$2.19M	Buy	+30,000	New	+$2.23M	1.34%	31

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $7.94B AUM 55.6% 1-Year Est. Return

JP Morgan Chase

JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return

Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Davidson Kempner Capital Management New York $4.65B AUM 56.47% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return